Home›Companies›Biotech & Pharma›Enterin

Enterin, Inc.

Updated Oct 27, 2026·Latest SEC filing Dec 6, 2023·Suggest an edit

About Enterin

Enterin is a private company based in Philadelphia, Pennsylvania. It has reported $50,655,945 raised in six offerings on Form D since July 2017. Its chief executive is David McCullough.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Nov 21, 2023Dec 6, 2023$5,099,772of $19.9M target4$1.2MEquityRule 506(b)Form D ↗
Aug 30, 2022Sep 12, 2022$6,000,000of $20.0M target3$2.0MDebt, Convertible SecuritiesRule 506(b)Form D ↗
Sep 23, 2021Oct 8, 2021$5,685,438of $32.0M target2$2.8MDebt, Convertible SecuritiesRule 506(b)Form D ↗
Sep 8, 2020Sep 16, 2020$11,703,493of $19.9M target9$1.3MEquityRule 506(b)Form D ↗
Jan 11, 2019Jan 28, 2019$16,699,970of $25.0M target6$2.7MEquityRule 506(b)Form D ↗
Jun 30, 2017Jul 14, 2017$5,467,272of $12.7M target21$260KEquityRule 506(b)Form D ↗
Total, six offerings$50,655,945

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Enterin's Form D filed Dec 6, 2023.

MZ
DM
David McCullough
Chief Executive Officer and director
BM
Barry Miller
Director
Also a director at Metabolics Pharma.
DM
Don Munoz
Director
KW
Katherine Wolf
Executive officer
RL
Richard Larson
Executive officer
Also a chief executive officer and director at Metabolics Pharma.
RM
Roger Mills
Director
WK
William Kinney
Executive officer
JB
Jay Brammer
Director
Also a director at Metabolics Pharma.
RP
MF
Mark Finn
Director
Also a director at Metabolics Pharma.

Earlier filings also listed Denise Barbut (executive officer and director, last listed Sep 2022), David Vogel (director, last listed Sep 2022), Stuart Barlow (chief financial officer, last listed Sep 2020) and Nancy Ness (executive officer, last listed Jan 2019).

Sources

  1. SECEnterin, Inc. filing history